

# SIMPLIFY AND SECURE YOUR BIOSAFETY QUALITY CONTROL WITH **NEXT GENERATION SEQUENCING (NGS)**



## Vaccines

## COMPLIANT, FASTER, ANIMAL-FREE



Adventitious Agent Testing | Identity Confirmation

### SIMPLIFIED VIRAL SAFETY TESTING



#### No neutralization needed:

Consistent and reproducible results  
that work the first time



#### Faster:

Comprehensive adventitious  
viral agent detection and  
identification in a single  
assay step



#### Safer:

Comprehensive viral  
breadth of detection



**Animal-Free:**  
3Rs compliant

### UNMATCHED PRECISION FOR GENETIC CHARACTERIZATION



#### Identity:

- High-resolution sequence verification
- Broad genomic coverage
- Detection of complex mixed populations

### REGULATORY GUIDELINES

- ICH Q5A(R2) – Viral safety (2023 revision)
- ICH Q5B – Expression construct analysis for production of r-DNA derived protein products
- ICH Q5D – Derivation and characterization of cell substrates
- EMA Guideline: EMA/CHMP/BWP/457920/2012 Rev.1
- FDA Guidance for the Industry: Points to consider in the characterization of cell lines (1993)
- FDA GUIDANCE for industry - Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications - 2010
- USP <1050> – Viral safety from cell lines of human and animal origin
- Ph Eur 2.6.16 – Tests for extraneous agents in viral vaccines for human use
- Ph. Eur. 5.2.14 – Substitution of in vivo method(s) by in vitro method(s) for the quality control of vaccines
- Ph. Eur. 5.2.3/5.1.7 – Cell substrates for the production of vaccines and biologicals and viral safety
- Ph. Eur. 2.6.41 – High-throughput sequencing for the detection of viral extraneous agents: New chapter adopted in March 2025
- WHO TRS No. 978, Annex 3 (2010) – Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks
- WHO Expert Committee on Biological Standardization\_80th report (2025)

### 2 GMP MIRROR FACILITIES




Wayne, PA



Paris



## UPSTREAM PROCESSING (USP)



## DOWNSTREAM PROCESSING (DSP)

### ASSAY SPECIFICATIONS

	Assay	GMP	Sample Requirements	Turnaround Time	Deliverables to Client
VIRAL SAFETY	<b>iDTECT® Transcriptome</b> For cell-based material	✓	Min. 3×10 <sup>5</sup> cells	5 weeks (Standard) 4 weeks (Fast Track)	<ul style="list-style-type: none"> <li>Certificate of Analysis</li> <li>Expert virologist report</li> <li>Raw data</li> </ul>
	<b>iDTECT® Virome</b> For cell-free material	✓	2×5 mL	6 weeks (Standard) 5 weeks (Fast Track)	<ul style="list-style-type: none"> <li>Certificate of Analysis</li> <li>Expert virologist report</li> <li>Raw data</li> </ul>
GENETIC CHARACTERIZATION	<b>iDTECT® Identity</b>	✓	Varies by sample type	3 weeks (Standard) 2 weeks (Fast Track)	<ul style="list-style-type: none"> <li>Certificate of Analysis (% identity match to reference, presence and nature of variants)</li> </ul>

Back up samples required. BSL1 and BSL2 samples accepted. | Shipment & storage: - 80°C/Dry Ice



#### CONTACT OUR EXPERTS

contact@pathoquest.com  
www.pathoquest.com

466 Devon Park Dr  
Wayne, PA 19087  
United States

Biopark - Bâtiment B,  
11, rue Watt  
75013 Paris, France

